Gilead Sciences Inc. Canadian Depositary Receipt (GILD)
NEO
Closed
Aug 21, 2026
Day's Range
29.2052 wk Range
22.49Overview - GILD - Gilead Sciences Inc. Canadian Depositary Receipt
Key Statistics
Valuation
Enterprise Value
66.97B
P/E (Trailing)
‪22.22‬
PEG Ratio
‪-0.03‬
Price / Sales (TTM)
‪8.55‬
Price / Book
‪1.23‬
EV / EBITDA
‪3.44‬
Profitability
Gross Margin
‪79.76%‬
Profit Margin
‪27.88%‬
Operating Margin
‪45.23%‬
Return on Assets
‪12.57%‬
Return on Equity
‪40.70%‬
Ownership
Shares Outstanding
1.24B
Float
1.23B
Price stats
Beta
‪0.33‬
50-Day Avg
‪25.75‬
200-Day Avg
‪23.98‬
Dividends
Payout Ratio
‪24.46%‬
Frequency
Quarterly
Shariah Compliance
Report Date: Feb 20, 2025
Screened by Zoya using the AAOIFI methodology.
Peers - GILD - Gilead Sciences Inc. Canadian Depositary Receipt
Peer Comparison
Compared with companies in Drug Manufacturers - General listed on NEO.
Profile Summary - GILD - Gilead Sciences Inc. Canadian Depositary Receipt
About
Gilead Sciences Inc. CDR represents a Canadian Depositary Receipt for Gilead Sciences Inc., a prominent biotechnology company specializing in the research, development, and commercialization of innovative therapies for life-threatening diseases. Known for its strong focus on infectious diseases, Gilead’s core…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
